3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Interventions
Carboplatin
11
pembrolizumab
10
Gemcitabine
8
Cisplatin
8
Rituximab
7
osimertinib
5
durvalumab
5
Specimen Handling
5
Pemetrexed
5
Nivolumab
5
Dexamethasone
5
belzutifan
4
atezolizumab
4
amivantamab
4
Prednisone
4
Paclitaxel
4
Cyclophosphamide
4
Bortezomib
4
trastuzumab deruxtecan
3
olaparib
3
lazertinib
3
entrectinib
3
enfortumab vedotin
3
daratumumab
3
alectinib
3
acalabrutinib
3
X-Rays
3
Vinorelbine
3
Oxaliplatin
3
Midazolam
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Gefitinib
×
90 days
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA